Form 4: Enanta Pharma VP Finance Receives Equity Grant

Enanta Pharmaceuticals' VP of Finance, Harry R. Trout III, was granted 6,463 restricted stock units and options to purchase 12,925 shares of common stock.

Summary

• Harry R. Trout III, Vice President, Finance (Principal Financial Officer) of Enanta Pharmaceuticals Inc. (ENTA), reported an acquisition of securities.
• On November 25, 2025, Mr. Trout was granted 6,463 shares of common stock in the form of Restricted Stock Units (RSUs) at a price of $0 per share.
• These RSUs will vest and settle with respect to 25% of the award on December 1, 2026, and in substantially equal annual installments over the next three anniversaries thereafter.
• Following this transaction, Mr. Trout beneficially owns 17,375 shares of common stock directly.
• Additionally, on November 25, 2025, Mr. Trout was granted stock options to purchase 12,925 shares of common stock at an exercise price of $13.66 per share.
• These stock options will become exercisable quarterly in substantially equal installments over four years from the grant date (November 25, 2025), subject to continued employment.
• The stock options have an expiration date of November 25, 2035.
• Following this transaction, Mr. Trout beneficially owns 12,925 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a key executive, which is generally a neutral to slightly positive event as it aligns management incentives with shareholder interests, without indicating any immediate operational or financial performance changes.

Positives

• The equity grants align the interests of a key financial officer with those of the shareholders, incentivizing long-term performance.
• The grants are made under the existing 2019 Equity Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The issuance of new equity (upon vesting/exercise) could lead to minor dilution for existing shareholders, though this is standard for equity compensation plans.

Risks

• The vesting of both RSUs and stock options is contingent upon the optionholder's continued employment with Enanta Pharmaceuticals, Inc.

Future Outlook

The filing details future vesting schedules for equity awards, with RSUs vesting 25% annually starting December 1, 2026, and stock options vesting quarterly over four years from November 25, 2025, contingent on continued employment.

Industry Context

Equity grants to key executives are a standard practice across the biotechnology and pharmaceutical industries to attract, retain, and incentivize talent, aligning management's long-term interests with company performance and shareholder value.

Stakeholder Impact

• Shareholders: Potential minor dilution from future share issuance upon vesting and exercise of equity awards, but also benefit from increased management incentive.
• Employees (specifically Harry R. Trout III): Enhanced compensation and long-term incentive, contingent on continued employment.

Next Steps

• Continued vesting of 25% of RSUs annually starting December 1, 2026.
• Continued quarterly vesting of stock options over four years from November 25, 2025.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Harry R. Trout III, Vice President Finance